MoFo News Item

MoFo Advises RA Capital/OrbiMed on $125M Series B Financing

20 Apr 2021

Morrison & Foerster represented RA Capital and OrbiMed as lead investors in Janux Therapeutics’ $125 million Series B financing. OrbiMed and RA Capital are two of the world’s leading healthcare venture capital firms. Janux Therapeutics is developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. RA Capital and OrbiMed were joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company) and Janux’s existing investors, Avalon Ventures, and Bregua.

MoFo previously represented RA Capital and OrbiMed in Janux’s $56 million Series A financing which closed in March 2021.

The MoFo team was led by San Diego corporate attorneys Jim Krenn, Brennen Brodersen, Andrew Dixon and Carey Hughes.

Further information regarding the financing.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.